It is well known that carbapenem antibiotics have broad-spectrum activities and strong bactericidal actions against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and gram-positive cocci except methicillin-resistant Staphylococcus aureus and metallo-β-lactamase-producing pathogens. Tebipenem is a new oral carbapenem antibiotic. Tebipenem was very active against the S. pneumoniae isolates, with MICs of 0.002 to 0.031 μg/ml for the gPISP isolates and 0.016 to 0.125 μg/ml for the gPRSP isolates. The MICs of Tebipenem ranged from ≤0.001 to 0.004 μg/ml for all PSSP and gPISP (2x) isolates. S. pneumoniae isolates ME19 (serotype 19F) cell wall synthesis stopped in the pneumococcal cells exposed to Tebipenem at 0.063 μg/ml (the MIC) and 0.125 μg/ml (two times the MIC) for 2 h, and the protrusions were pulled in the direction of the long axis with the swelling of the cell[3]. In mouse, rat, dog and monkey, Tebipenem were absorbed quickly, and the bioavailability was 71.4, 59.1, 34.8 and 44.9%, respectively. After single oral administration of 10 mg/kg 14C-Tebipenem to rat, 36.9-42.7% and 58.3-62.2% of radioactivity was excreted to urine and feces, respectively, by 120 hours after administration[4].
搜索
